Endocrinology, Vol 136, 3194-3199, Copyright © 1995 by Endocrine Society

ARTICLES

Repression of endogenous estrogen receptor activity in MCF-7 human breast cancer cells by dominant negative estrogen receptors

BA Ince, DJ Schodin, DJ Shapiro and BS Katzenellenbogen
Department of Cell and Structural Biology, University of Illinois, Urbana 61801, USA.

We have investigated the ability of several transcriptionally inactive estrogen receptor (ER) mutants to block endogenous ER-mediated transcription in MCF-7 human breast cancer cells. In transient transfections of MCF-7 cells, two of the mutants, a frame-shifted ER (S554fs) and a point-mutated ER (L540Q), strongly inhibit the ability of endogenous wild-type ER to activate transcription of estrogen- regulated reporter plasmids. A third mutant, ER1-530, which is missing 65 residues from its carboxy-terminus, is a weaker repressor of estradiol-stimulated transcription. When an estrogen response element (ERE)-thymidine kinase-chloramphenicol acetyltransferase reporter gene is used, S554fs, L540Q, and ER1-530 suppress the transcriptional activity of endogenous MCF-7 ER by 87%, 97%, and 62%, respectively. The magnitude of dominant negative repression is promoter specific; when an ERE-pS2-chloramphenicol acetyltransferase reporter is employed, inhibition of endogenous ER activity by equivalent amounts of S554fs, L540Q, and ER1-530 ranges from 85-97%. Dose-response studies show the S554fs mutant to be the most potent of the three ER mutants as a repressor of estrogen action in these cells. In addition, elevated levels of intracellular cAMP, achieved by the addition of 3-isobutyl-1- methylxanthine plus cholera toxin to cells, fail to compromise the effectiveness of these mutants as dominant negative ERs despite the cAMP-enhanced transcriptional activity of ER. The mutants are also powerful repressors of the agonist activity of trans-hydroxytamoxifen- stimulated ER transcription. The dominant negative activity of the three mutants is lost when the A/B domain of these receptors is deleted, implying an important role for this N-terminal region of the ER in the ability of these mutants to inhibit endogenous wild-type ER activity. All in all, the data suggest that S554fs in particular is a reasonable candidate for studies designed to use a dominant negative ER to inhibit the estrogen- and tamoxifen-stimulated growth of human breast cancer cells.

This article has been cited by other articles:

				E. J. Lee and J L. Jameson Gene therapy of pituitary diseases J. Endocrinol., June 1, 2005; 185(3): 353 - 362. [Abstract] [Full Text] [PDF]

				M. H. Herynk and S. A. W. Fuqua Estrogen Receptor Mutations in Human Disease Endocr. Rev., December 1, 2004; 25(6): 869 - 898. [Abstract] [Full Text] [PDF]

				S. T. Pearce, H. Liu, and V. C. Jordan Modulation of Estrogen Receptor alpha Function and Stability by Tamoxifen and a Critical Amino Acid (Asp-538) in Helix 12 J. Biol. Chem., February 21, 2003; 278(9): 7630 - 7638. [Abstract] [Full Text] [PDF]

				J. A. Schwartz, L. Zhong, S. Deighton-Collins, C. Zhao, and D. F. Skafar Mutations Targeted to a Predicted Helix in the Extreme Carboxyl-terminal Region of the Human Estrogen Receptor-alpha Alter Its Response to Estradiol and 4-Hydroxytamoxifen J. Biol. Chem., April 5, 2002; 277(15): 13202 - 13209. [Abstract] [Full Text] [PDF]

				J. Sun, Y. R. Huang, W. R. Harrington, S. Sheng, J. A. Katzenellenbogen, and B. S. Katzenellenbogen Antagonists Selective for Estrogen Receptor {alpha} Endocrinology, March 1, 2002; 143(3): 941 - 947. [Abstract] [Full Text] [PDF]

				E. J. Lee, W. R. Duan, M. Jakacka, B. D. Gehm, and J. L. Jameson Dominant Negative ER Induces Apoptosis in GH4 Pituitary Lactotrope Cells and Inhibits Tumor Growth in Nude Mice Endocrinology, September 1, 2001; 142(9): 3756 - 3763. [Abstract] [Full Text] [PDF]

				P.-Y. Chien, M. Ito, Y. Park, T. Tagami, B. D. Gehm, and J. L. Jameson A Fusion Protein of the Estrogen Receptor (ER) and Nuclear Receptor Corepressor (NCoR) Strongly Inhibits Estrogen-Dependent Responses in Breast Cancer Cells Mol. Endocrinol., December 1, 1999; 13(12): 2122 - 2136. [Abstract] [Full Text]

				M. M. Montano, K. Ekena, R. Delage-Mourroux, W. Chang, P. Martini, and B. S. Katzenellenbogen An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens PNAS, June 8, 1999; 96(12): 6947 - 6952. [Abstract] [Full Text] [PDF]

				Y. Lavrovsky, R. K. Tyagi, S. Chen, C. S. Song, B. Chatterjee, and A. K. Roy Ribozyme-Mediated Cleavage of the Estrogen Receptor Messenger RNA and Inhibition of Receptor Function in Target Cells Mol. Endocrinol., June 1, 1999; 13(6): 925 - 934. [Abstract] [Full Text]

				G. Lazennec, J. L. Alcorn, and B. S. Katzenellenbogen Adenovirus-Mediated Delivery of a Dominant Negative Estrogen Receptor Gene Abrogates Estrogen-Stimulated Gene Expression and Breast Cancer Cell Proliferation Mol. Endocrinol., June 1, 1999; 13(6): 969 - 980. [Abstract] [Full Text]

				V. Budhram-Mahadeo, M. Parker, and D. S. Latchman POU Transcription Factors Brn-3a and Brn-3b Interact with the Estrogen Receptor and Differentially Regulate Transcriptional Activity via an Estrogen Response Element Mol. Cell. Biol., February 1, 1998; 18(2): 1029 - 1041. [Abstract] [Full Text]

				W. Gong, S. Chávez, and M. Beato Point Mutation in the Ligand-Binding Domain of the Progesterone Receptor Generates a Transdominant Negative Phenotype Mol. Endocrinol., September 1, 1997; 11(10): 1476 - 1485. [Abstract] [Full Text]

				P. M. Yen, Y. Liu, J. J. Palvimo, M. Trifiro, J. Whang, L. Pinsky, O. A. Jänne, and W. W. Chin Mutant and Wild-Type Androgen Receptors Exhibit Cross-Talk on Androgen-, Glucocorticoid-, and Progesterone-Mediated Transcription Mol. Endocrinol., February 1, 1997; 11(2): 162 - 171. [Abstract] [Full Text]

				R. Delage-Mourroux, P. G. V. Martini, I. Choi, D. M. Kraichely, J. Hoeksema, and B. S. Katzenellenbogen Analysis of Estrogen Receptor Interaction with a Repressor of Estrogen Receptor Activity (REA) and the Regulation of Estrogen Receptor Transcriptional Activity by REA J. Biol. Chem., November 10, 2000; 275(46): 35848 - 35856. [Abstract] [Full Text] [PDF]